Table 1.
Overview of patients’ characteristics according to TMB values.
| Variation | Total | TMB < 10 | TMB > 10 | ||||
|---|---|---|---|---|---|---|---|
| N = 417 | N = 260 | (62.35%) | N = 157 | (37.65%) | |||
| Age | Median | 66 | 66 | 66 | |||
| Mean (±SD) | 65.0 | (11.8) | 64.7 | (12.5) | 65.7 | (10.5) | |
| Range | 21–92 | 21–92 | 93–90 | ||||
| <65 years | 199 | (47.72%) | 126 | (48.46%) | 73 | (46.50%) | |
| ≥65 years | 218 | (52.28%) | 134 | (51.54%) | 84 | (53.50%) | |
| Sex | Female | 177 | (42.45%) | 140 | (53.85%) | 100 | (63.69%) |
| Male | 240 | (57.55%) | 120 | (46.15%) | 57 | (36.31%) | |
| Histology | Adenocarcinoma | 308 | (73.86%) | 201 | (77.31%) | 107 | (68.15%) |
| Squamous | 33 | (7.91%) | 14 | (5.38%) | 19 | (12.10%) | |
| Adeno-squamous | 1 | (0.24%) | 1 | (0.38%) | |||
| Large-cell neuroendocrine | 2 | (0.48%) | 2 | (1.27%) | |||
| SCLC | 4 | (0.96%) | 4 | (1.54%) | |||
| NOS | 69 | (16.55%) | 40 | (15.38%) | 29 | (18.47%) | |
| EGFR Status | Mutant | 62 | (14.87%) | 47 | (18.08%) | 15 | (9.55%) |
| Wild type | 355 | (85.13%) | 213 | (81.92%) | 142 | (90.45%) | |
| targetable EGFR mutation | 41 | (66.13%) | 33 | (12.69%) | 8 | (5.10%) | |
| targetable EGFR plus resistance mutation T790M | 3 | (4.84%) | 3 | (1.15%) | |||
| EGFR exon 20 insertion | 6 | (9.68%) | 6 | (2.31%) | |||
| other / variant of unknown significance | 12 | (19.35%) | 5 | (1.92%) | 7 | (4.46%) | |
| BRAF Status | Mutant | 36 | (8.63%) | 20 | (7.69%) | 16 | (10.19%) |
| Wild type | 381 | (91.37%) | 240 | (92.31%) | 141 | (89.81%) | |
| V600E / class I * | 9 | (25.00%) | 8 | (3.08%) | 1 | (0.64%) | |
| non-V600E / class II * | 11 | (30.56%) | 5 | (1.92%) | 6 | (3.82%) | |
| non-V600E / class III * | 5 | (13.89%) | 3 | (1.15%) | 2 | (1.27%) | |
| other mutation / variant of unknown significance | 11 | (30.56%) | 4 | (1.54%) | 7 | (4.46%) | |
| Gene Fusions | Mutant | 41 | (9.83%) | 32 | (12.31%) | 9 | (5.73%) |
| Wild type | 368 | (88.25%) | 223 | (85.77%) | 145 | (92.36%) | |
| n.d. | 8 | (1.92%) | 5 | (1.92%) | 3 | (1.91%) | |
| ALK translocation | 15 | (36.59%) | 14 | (5.38%) | 1 | (0.64%) | |
| ROS1 translocation | 2 | (4.88%) | 1 | (0.38%) | 1 | (0.64%) | |
| RET translocation | 3 | (7.32%) | 3 | (1.15%) | |||
| other fusions / translocation of unknown significance | 21 | (51.22%) | 14 | (5.38%) | 7 | (4.46%) | |
| PD-L1 TPS | <1% | 123 | (29.50%) | 79 | (30.38%) | 44 | (28.03%) |
| ≥1% and <5% | 50 | (11.99%) | 26 | (10.00%) | 24 | (15.29%) | |
| ≥5% and <50% | 79 | (18.94%) | 55 | (21.15%) | 24 | (15.29%) | |
| ≥50% | 99 | (23.74%) | 53 | (20.38%) | 46 | (29.30%) | |
| n.d. | 66 | (15.83%) | 47 | (18.08%) | 19 | (12.10%) | |
* BRAF mutations were classified based on Yao et al. [26].